Logos Global Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $18.9M | Buy |
+150,000
| New | +$18.9M | 2.09% | 14 |
|
|
2025
Q1 | – | Sell |
-200,000
| Closed | -$27.3M | – | 51 |
|
|
2024
Q4 | $27.3M | Buy |
+200,000
| New | +$27.3M | 3.19% | 11 |
|
|
2023
Q4 | – | Sell |
-150,000
| Closed | -$16.9M | – | 58 |
|
|
2023
Q3 | $16.9M | Sell |
150,000
-150,000
| -50% | -$16.9M | 2.25% | 14 |
|
|
2023
Q2 | $28.3M | Buy |
300,000
+100,000
| +50% | +$9.43M | 3.85% | 9 |
|
|
2023
Q1 | $20.2M | Buy |
+200,000
| New | +$20.2M | 2.9% | 12 |
|
|
2022
Q3 | – | Sell |
-300,000
| Closed | -$29.2M | – | 42 |
|
|
2022
Q2 | $29.2M | Sell |
300,000
-175,000
| -37% | -$17.1M | 5.37% | 6 |
|
|
2022
Q1 | $44.5M | Buy |
+475,000
| New | +$44.5M | 5.77% | 5 |
|